Recombinant NAPc2

Drug Profile

Recombinant NAPc2

Alternative Names: NAPc2; Nematode Anticoagulant Protein c2; Recombinant Nematode Anticoagulant c2; rNAPc2

Latest Information Update: 12 Dec 2014

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Anticoagulants; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Colorectal cancer; Deep vein thrombosis; Disseminated intravascular coagulation; Ebola virus infections

Most Recent Events

  • 10 Dec 2014 Recombinant NAPc2 receives Orphan Drug status for Ebola virus infections in USA
  • 10 Dec 2014 rNAPc2 is available for licensing as of 05 Oct 2012. www.arcabiopharma.com
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top